Position in NBP
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$2,402,294
+$2,378,808 QoQ
Shares Held
1,231,946
+8659.6% QoQ
Ownership
1.07%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#5
of 49 holders
Holding Since
Sep 2020
8 quarters on record
Voting authority
Sole 0%
Shared 100%
None 0%
Common Shares in NBP Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026MARSHALL WACE, LLP holds $3,055,517,440 across 267 Biotechnology names. NBP ranks #137 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
543,897 | $270,169,956 | |
| 2 | INCY |
Incyte Corp
|
1,310,154 | $148,519,056 | |
| 3 | RPRX |
Royalty Pharma plc
|
2,450,669 | $137,409,009 | |
| 4 | SYRE |
Spyre Therapeutics, Inc.
|
991,693 | $88,042,503 | |
| 5 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
259,799 | $78,207,292 | |
| 6 | TVTX |
Travere Therapeutics, Inc.
|
1,333,207 | $75,739,488 | |
| 7 | MANE |
Veradermics, Inc
|
585,560 | $71,988,746 | |
| 8 | DFTX |
Definium Therapeutics, Inc.
|
1,298,946 | $61,102,419 |
All Filings in NBP
Export CSV
8 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,402,294 | 1,231,946 | Shares | Other | 2026-08-13 | |
| 2024-06-30 | $23,486 | 14,064 | Shares | Other | 2024-08-14 | |
| 2024-03-31 | $132,222 | 71,088 | Shares | Other | 2024-05-15 | |
| 2022-06-30 | $1,180,601 | 104,478 | Shares | Other | 2022-08-15 | |
| 2021-12-31 | $607,538 | 12,820 | Shares | Other | 2022-02-14 | |
| 2021-03-31 | $2,597,798 | 53,596 | Shares | Sole | 2021-05-17 | |
| 2020-12-31 | $7,114,227 | 150,885 | Shares | Sole | 2021-02-16 | |
| 2020-09-30 | $3,508,296 | 74,597 | Shares | Sole | 2020-11-16 | |
| No filing history on record for this holder in this stock. | ||||||